ergic system via reversing acetyl choline
(ACh) depletion, reducing choline acety-lase activity and decreasing muscarinic
receptor binding (see Table 1).
Data from human studies are consistent
with results from animal studies. Several
double-blind, placebo-controlled studies
(both chronic and acute) demonstrated
significant improvement in early information processing, verbal learning, memory
consolidation and decreased the rate of
forgetting newly acquired information
with KeenMind treatment (see Table 2).
Several previous human trials concluded that Bacopa extract used in KeenMind
is a relatively safe and effective option for
the treatment of age-related memory impairment. Further studies are required to
ascertain the longer term effects of administration; potential therapeutic effects
of Brahmi for AD will also need to be validated in AD patients. NW
Barnes PM, et al. 2008. Complementary and
alternative medicine use among adults and
children: United States, 2007. CDC National
Health Statistics Report no. 12.
Chang, D, et al. 2011. Complementary thera-
pies for Alzheimer’s disease. Encyclopaedic
book, “Dementia” (4th edition, eds. Ames,
O’Brien and Burns), Hodder,U.K. Chapter
Dubey NK, et al. 2004. Global promotion of
herbal medicine: India’s opportunity. Current
Science. 86: 37–41.
Farlow MR, et al. 2008. Treatment op-
tions in Alzheimer’s disease: Maximizing
benefit, managing expectations. Demen-
tia and Geriatic Cognitive Disorders. 25: